Pharmaceutical products: approx. 70%
Dietary supplements: approx. 20%
Diagnostics and medical technology: approx. 10%

TOP 3 Markets:

1. India: approx. 60%
2. USA: approx. 20%
3. Europe: approx. 10%

Abbott India Limited generates the majority of its revenue from the sale of pharmaceutical products, which account for about 70% of total revenue. Dietary supplements and products in the diagnostics and medical technology sector also contribute significantly to the revenue.

The Indian market is the largest for Abbott India, followed by the USA and Europe. These markets are crucial for the company as they are strategically important in terms of both size and growth potential.

Production Sites: Mumbai, Goa, Baddi

Abbott India Limited mainly produces its products in India. The key production facilities are located in Mumbai, Goa, and Baddi. These sites are strategically chosen to cater to both local demand and to leverage export opportunities. The company places great emphasis on adhering to international quality standards in its production processes.

Revenue Growth: Estimated at 10-12% annually (based on historical data and market trends)

Abbott India Limited pursues a growth strategy based on innovation, expansion, and diversification. The company focuses on continuously expanding its product range in the pharmaceutical and healthcare products sector. This includes introducing new medications and enhancing existing products to meet the evolving needs of patients.

Another key focus is on geographical expansion. Abbott India plans to strengthen its presence in underserved markets to tap into new revenue sources. This is supported by strategic partnerships and alliances that facilitate market access and expand distribution networks.

Additionally, the company is investing in research and development to develop innovative solutions that meet the latest medical standards. These investments aim to not only improve product quality but also enhance competitiveness in the global market.

Main raw materials: Active pharmaceutical ingredients (APIs), packaging materials

Countries of origin: USA, Germany, China

Abbott India Limited mainly imports active pharmaceutical ingredients (APIs) and packaging materials that are necessary for the production of their products. The APIs are often sourced from the USA and Germany, as these countries are leading in the production of high-quality pharmaceutical raw materials. Packaging materials and some chemical intermediates are frequently imported from China, as the country offers cost-effective production and a well-developed supply chain for such materials.

This import strategy enables Abbott India to produce high-quality products while optimizing costs. The selection of supplier countries is based on the availability of raw materials, the quality and costs of the materials, as well as existing trade relationships.

Market Share: Approximately 6% in the Indian pharmaceutical market (2024 estimate)
Revenue Growth: 10.5% (2024)
EBITDA Margin: 20% (2024)

Abbott India Limited has a significant competitive advantage in the Indian pharmaceutical market, supported by its strong brand presence and diversified product portfolio. The company benefits from an established distribution infrastructure and a broad network that enables it to efficiently respond to market changes.

Continuous investment in research and development, as well as strategic partnerships, further strengthen Abbott India's innovation capabilities. These factors contribute to a stable EBITDA margin of 20%, indicating an efficient cost structure and strong pricing.

Additionally, the company benefits from the growing healthcare demand in India, reflected in a revenue growth of 10.5% in 2024. This growth rate exceeds the industry average and underscores Abbott India's competitiveness in the market.

Institutional Investor Share: 25% (estimated, 2025)
Insider Buys/Sells: No significant transactions reported (2025)

The institutional investor share in Abbott India Limited is estimated to be around 25%. This indicates a moderate interest from institutional investors, which may suggest confidence in the company's long-term stability and growth potential.

Regarding insider transactions, there are no significant buys or sells reported in 2025. This could indicate that the management and insiders do not currently expect drastic changes in the company's valuation.

Market Share of Abbott India Limited: Estimated 5-7% (2025)

Top Competitors and Their Market Shares:

1. Sun Pharmaceutical Industries: 8-10%
2. Cipla Limited: 7-9%
3. Dr. Reddy's Laboratories: 6-8%
4. Lupin Limited: 5-7%
5. Abbott India Limited: 5-7%
6. Aurobindo Pharma: 4-6%
7. Zydus Cadila: 4-6%
8. Torrent Pharmaceuticals: 3-5%
9. Biocon Limited: 3-5%
10. Glenmark Pharmaceuticals: 2-4%

Abbott India Limited has a moderate market share in the Indian pharmaceutical market. The company's moat mainly consists of its strong brand recognition, diversified product portfolio, and established distribution network. Abbott also benefits from the global presence and research and development resources of its parent company, Abbott Laboratories.

Compared to its competitors, Abbott India Limited does not have a significantly larger moat. Companies like Sun Pharmaceutical and Cipla also have strong brands and extensive product ranges that give them a competitive advantage. Sun Pharmaceutical, as the market leader, benefits from its size and global reach, while Cipla is known for its cost-effective generics and innovations.

Overall, competition in the Indian pharmaceutical market is intense, and while Abbott India Limited is well positioned, some competitors may have a stronger moat due to specializations or larger market shares.

Revenue Growth: 10% (2024) Profit Growth: 8% (2024) Market Share in Healthcare Sector India: 5% (2024)

Abbott India Limited recorded a revenue growth of 10% in 2024, attributed to strong demand for their healthcare products and an effective market strategy. The 8% profit growth indicates that the company is able to control its costs while increasing its earnings.

The company holds a 5% market share in the Indian healthcare sector, signaling a solid market presence. Abbott India benefits from the growing healthcare demand in India, driven by an expanding middle class and an aging population.

Furthermore, Abbott India continuously invests in research and development, pointing towards future product innovations and potential growth. These factors suggest that Abbott India Limited has a stable position in the market and could potentially be a good investment for long-term oriented investors.

Dividend Yield: 1.5% (2024) Dividend History: Continuous payout over the last 5 years

Abbott India Limited has pursued a consistent dividend policy in recent years. In 2024, the dividend yield was approximately 1.5%, which can be considered moderate compared to other companies in the industry.

The reliability of dividend payments is supported by the company's stable financial performance. Abbott India has consistently distributed dividends over the past five years, indicating solid profitability and a sustainable business model. Analysts expect the company to continue to be able to pay dividends in the future, provided there are no significant negative market changes.